<info type="DiseaseOrPhenotypicFeature">anemia</info> in patients infected with <info type="OrganismTaxon">hepatitis C virus</info>.

Chronic infection with <info type="OrganismTaxon">hepatitis C virus</info> (<info type="GeneOrGeneProduct">HCV</info>) can progress to <info type="DiseaseOrPhenotypicFeature">cirrhosis</info>, <info type="DiseaseOrPhenotypicFeature">hepatocellular carcinoma</info>, and <info type="DiseaseOrPhenotypicFeature">end-stage liver disease</info>. The current best treatment for <info type="OrganismTaxon">HCV</info> infection is combination therapy with <info type="ChemicalEntity">pegylated interferon</info> and <info type="ChemicalEntity">ribavirin</info>. Although this regimen produces <info type="DiseaseOrPhenotypicFeature">sustained virologic responses</info> (SVRs) in approximately 50% of patients, it can be associated with a potentially dose-limiting <info type="DiseaseOrPhenotypicFeature">hemolytic anemia</info>. <info type="GeneOrGeneProduct">Hemoglobin</info> concentrations decrease mainly as a result of <info type="ChemicalEntity">ribavirin</info>-induced <info type="DiseaseOrPhenotypicFeature">hemolysis</info>, and this <info type="DiseaseOrPhenotypicFeature">anemia</info> can be problematic in patients with <info type="OrganismTaxon">HCV</info> infection, especially those who have comorbid <info type="DiseaseOrPhenotypicFeature">renal</info> or <info type="DiseaseOrPhenotypicFeature">cardiovascular disorders</info>. In general, <info type="DiseaseOrPhenotypicFeature">anemia</info> can increase the risk of morbidity and mortality, and may have negative effects on <info type="DiseaseOrPhenotypicFeature">cerebral function</info> and quality of life. Although <info type="ChemicalEntity">ribavirin</info>-associated <info type="DiseaseOrPhenotypicFeature">anemia</info> can be reversed by dose reduction or discontinuation, this approach compromises outcomes by significantly decreasing SVR rates. <info type="GeneOrGeneProduct">Recombinant human erythropoietin</info> has been used to manage <info type="ChemicalEntity">ribavirin</info>-associated <info type="DiseaseOrPhenotypicFeature">anemia</info> but has other potential disadvantages. <info type="ChemicalEntity">Viramidine</info>, a liver-targeting prodrug of <info type="ChemicalEntity">ribavirin</info>, has the potential to maintain the virologic efficacy of <info type="ChemicalEntity">ribavirin</info> while decreasing the risk of <info type="DiseaseOrPhenotypicFeature">hemolytic anemia</info> in patients with chronic <info type="OrganismTaxon">hepatitis C</info>.